Tag: ISO 13485

Posted on by

Building IVD Compliance Pathways Through Effective Regulatory Strategies

Introduction

In vitro diagnostic (IVD) medical devices play a critical role in healthcare decision-making, influencing approximately 70% of all clinical decisions. As these technologies advance and global markets expand, navigating the complex regulatory landscape has become increasingly challenging for manufacturers. The path to compliance requires strategic planning, thorough understanding of regulatory frameworks, and implementation of robust quality management systems.

Effective regulatory strategies for IVD manufacturers seek to navigate compliance pathways efficiently and successfully bring their products to market across global jurisdictions, including UK, EU and USA.

The Evolving IVD Regulatory Landscape

IVDR in Europe: A Paradigm Shift

The European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) marked a significant evolution from the previous In Vitro Diagnostic Directive (IVDD 98/79/EC). This transition brought more stringent requirements, including:

  • Risk-based classification system (Classes A, B, C, and D)
  • Enhanced clinical evidence requirements
  • Increased post-market surveillance
  • Greater involvement of Notified Bodies
  • Unique Device Identification (UDI) implementation

The IVDR’s phased implementation continues to present challenges for manufacturers, particularly those with legacy products requiring recertification or first-time market entrants.

FDA Approach to IVDs

In the United States, the Food and Drug Administration (FDA) regulates IVDs as medical devices, categorizing them primarily through:

  • Class I: General controls (lowest risk)
  • Class II: Special controls and often 510(k) premarket notification
  • Class III: Premarket Approval (PMA) for highest risk devices

Global Harmonization Efforts

The International Medical Device Regulators Forum (IMDRF) continues to work toward harmonizing regulatory approaches worldwide. However, significant differences remain among jurisdictions, creating challenges for manufacturers pursuing global market access. The utilisation of IMDRF can be a valuable tool to develop a ‘one size fits all’ technical file – although this doesn’t quite work in practise. The Uks indication of using IMDRF principles is a welcome signal which may support future international recognition.

Building Strategic Compliance Pathways

1. Early Regulatory Strategy Development

Successful IVD manufacturers integrate regulatory planning into their product development lifecycle from inception. Key elements include:

  • Regulatory roadmapping: Documenting intended markets, timelines, and certification requirements
  • Classification determination: Early assessment of product risk classification across target jurisdictions
  • Regulatory intelligence gathering: Monitoring evolving requirements and guidance documents
  • Stakeholder alignment: Ensuring business, R&D, quality, and regulatory teams share understanding and objectives

Early strategic planning significantly reduces time-to-market and development costs by avoiding regulatory surprises and rework. It is important to consider the end goal – market access, and work backwards, when developing your design and development strategies.

2. Risk-Based Approach to Compliance

Implementing a risk-based approach aligns with modern regulatory frameworks and optimizes resource allocation:

  • Product risk classification: Understanding how regulatory bodies will classify your device
  • Risk management process: Implementing ISO 14971 principles throughout the product lifecycle
  • Benefit-risk analysis: Documenting how benefits outweigh residual risks
  • Risk-based quality management: Focusing QMS efforts proportionally to risk areas

This approach ensures compliance while maintaining operational efficiency. While this is a requirement to meet regulatory requirements, done right, this can add real value to the development and operational efficiency of IVD manufacturing in conjunction with ISO 13485

3. Building Robust Clinical Evidence

Enhanced clinical evidence requirements represent one of the most significant challenges in modern IVD regulation:

  • Scientific validity: Establishing the analyte’s association with clinical condition
  • Analytical performance: Demonstrating technical performance characteristics
  • Clinical performance: Providing evidence of clinical utility and outcomes
  • State-of-the-art analysis: Comparing performance against current alternatives
  • Literature-based strategies: Leveraging existing scientific literature effectively

For novel IVDs, well-designed clinical performance studies with clearly defined endpoints are increasingly essential.

4. Comprehensive Quality Management Systems

A robust QMS serves as the foundation for sustainable compliance:

  • ISO 13485:2016 implementation: Adopting the international standard for medical device QMS
  • Process approach: Defining interconnected processes with clear ownership
  • Design controls: Implementing systematic design and development procedures
  • Supplier management: Controlling purchased components and services
  • Post-market surveillance: Establishing vigilance and feedback systems

Integrated QMS software solutions can streamline documentation and enhance traceability across regulatory jurisdictions.

For the European Union (IVDR), Manufacturers are expected to have a compliant QMS to IVDR from June 2025.

5. Documentation and Technical File Preparation

Strategic documentation management is critical for efficient submissions:

  • Common Technical Documentation (CTD): Organizing technical files in internationally recognized formats
  • Modular approach: Designing core documentation adaptable to different jurisdictions
  • Traceability matrices: Ensuring regulatory requirements are comprehensively addressed
  • Gap analysis tools: Identifying and addressing documentation deficiencies

Electronic document management systems with regulatory intelligence capabilities can significantly enhance efficiency.

For the EU, many Notified Bodies provide guidance and template structures for how they expect to see Technical Documentation to be constructed. For classes B to D, it is recommended to engage with your NB early and understand their expectations of the conformity assessment process.

Advanced Regulatory Strategies for Complex Challenges

Companion Diagnostics

As precision medicine advances, companion diagnostics face unique challenges requiring coordinated regulatory strategies:

  • Drug-diagnostic co-development: Aligning timelines with pharmaceutical partners
  • Combined submissions: Navigating coordinated reviews between device and drug divisions
  • Harmonized clinical studies: Designing trials that satisfy both diagnostic and therapeutic endpoints

Early engagement with regulatory authorities through pre-submission meetings is particularly valuable for companion diagnostics.

Software as a Medical Device (SaMD)

IVDs increasingly incorporate software components or exist entirely as software, requiring specialized regulatory approaches:

  • SaMD framework implementation: Applying IMDRF risk categorization principles
  • Cybersecurity considerations: Addressing security by design principles
  • Artificial intelligence/machine learning: Navigating evolving regulatory expectations for adaptive algorithms
  • Agile development: Reconciling iterative development with regulatory requirements

The FDA’s Digital Health Software Precertification Program signals evolving approaches to software regulation that may influence other jurisdictions.

Point-of-Care and Self-Testing IVDs

Decentralized testing presents unique regulatory considerations:

  • Usability engineering: Demonstrating safe use by intended users
  • Human factors studies: Collecting evidence in simulated use environments
  • Simplified instructions: Developing clear usage guidance for lay users
  • Risk mitigation: Implementing safeguards against user error

Regulatory expectations for usability have increased significantly, particularly for tests intended for self-administration.

Creating Sustainable Compliance

Regulatory Intelligence Systems

Maintaining current regulatory intelligence is essential for sustainable compliance:

  • Monitoring mechanisms: Establishing systems to track regulatory changes
  • Gap assessment processes: Evaluating impact on existing products and pipelines
  • Strategic response planning: Developing action plans for significant regulatory shifts
  • Knowledge management: Maintaining institutional regulatory expertise

Subscription services and industry associations can provide valuable regulatory intelligence resources. Examples include our partners Medboard.

Post-Market Compliance Strategies

Regulatory responsibility extends well beyond initial approval:

  • Post-market surveillance planning: Designing proportionate monitoring systems
  • Real-world evidence collection: Gathering data on performance in clinical settings
  • Periodic safety update reports: Preparing comprehensive safety summaries
  • Change management: Navigating modifications to approved devices

Proactive post-market strategies can identify issues early and support expanded indications.

Building Regulatory Partnerships

Successful manufacturers view regulatory bodies as partners rather than obstacles:

  • Pre-submission consultations: Engaging early with authorities on novel technologies
  • Scientific advice meetings: Seeking input on clinical evidence plans
  • Regulatory inspections: Approaching audits as improvement opportunities
  • Transparent communication: Maintaining open dialogue about challenges

Building positive regulatory relationships creates pathways for more efficient future submissions.

Conclusion

The evolving IVD regulatory landscape presents significant challenges but also opportunities for manufacturers who implement strategic approaches to compliance. By integrating regulatory considerations throughout the product lifecycle, adopting risk-based methodologies, generating robust clinical evidence, and maintaining adaptable quality systems, manufacturers can navigate compliance pathways more efficiently.

Success in today’s regulatory environment requires not just understanding current requirements but anticipating future developments. Organizations that view regulatory strategy as a competitive advantage rather than a necessary burden are better positioned to bring innovative diagnostic solutions to patients while maintaining compliance across global markets.

As the diagnostic landscape continues to evolve with technological advances in digital health, precision medicine, and point-of-care testing, regulatory strategies must likewise adapt. By building sustainable compliance systems and fostering positive relationships with regulatory authorities, IVD manufacturers can create pathways to market that support innovation while ensuring safety and efficacy.

How can we help?

IVDeology has a long history of working with IVD manufacturers to define their regulatory strategy based on their company goals and objectives. We establish long term partnerships with our customers to ensure they meet the regulatory requirements for market access, and through the post market phase. To learn more about how we can help, contact [email protected].

Posted on by

How to Get Your QMS Ready for IVDR (25 May 2025)

With less than a month to go before the requirement kicks in for a valid Quality Management System (QMS) complaint to the EU IVD Regulation (IVDR), most IVD manufacturers who have placed IVDs on the European market (or any region where you are using the CE mark, including the UK) should be ready for the change.

If you are not one of them, you need to start thinking about the below very quickly!

A Strategic Approach for IVD Companies
The IVDR represents one of the most significant regulatory shifts for IVD manufacturers in recent history. With stricter requirements for quality management systems, technical documentation, and post-market surveillance, achieving IVDR compliance demands a comprehensive transformation of your existing quality processes. Here’s how to prepare your QMS effectively.


Understand the IVDR QMS Requirements
The IVDR significantly enhances the QMS expectations compared to the previous IVD directive (IVDD).


The regulation specifically references ISO 13485:2016 as a presumption of conformity, making this standard the foundation for IVDR-compliant quality systems. The EU harmonised version of this standard, EN ISO 13485:2016A11:2021, includes the handy Annex Z correspondence between the IVDR and ISO 13485


Gap Analysis: Your First Critical Step
Before implementing changes, conduct a thorough gap analysis of your current QMS against IVDR requirements:

  • Review existing procedures against IVDR Article 10 (manufacturer obligations), Annex I (general safety and performance requirements), and Annex IX (QMS and technical documentation assessment)
  • Assess your product classifications under the new risk-based system (Classes A through D)
  • Identify documentation gaps, particularly around clinical evidence and performance evaluation
  • Evaluate your post-market processes for alignment with intensified surveillance requirements

A structured gap analysis provides a clear roadmap of required changes and helps prioritize critical areas.


Key QMS Modifications for IVDR Compliance

1. Risk Management Integration
The IVDR requires risk management to be integrated throughout your QMS, not just during design phases:

  • Update your risk management procedure to align with ISO 14971:2019
  • Establish risk controls that span the entire product lifecycle
  • Implement benefit-risk analysis methodologies
  • Create documentation that demonstrates continuous risk assessment


2. Performance Evaluation System
Develop a robust performance evaluation system that includes:

  • Scientific validity assessment for each analyte
  • Analytical performance verification
  • Clinical performance studies (where applicable)
  • A performance evaluation plan and report (PER)
  • Documented procedures for updating performance evaluation throughout the product lifecycle


3. Post-Market Surveillance System
Strengthen your post-market surveillance (PMS) system to include:

  • A PMS plan specific to each device
  • A PMS report (for Class A and B devices) or periodic safety update report (PSUR) for Class C and D devices
  • Trend reporting for incidents
  • Processes for implementing field safety corrective actions (FSCAs)
  • Integration of PMS data into risk management and performance evaluation.

4. Supply Chain Oversight
The IVDR places greater responsibility on manufacturers for supplier and distributor oversight:

  • Develop procedures for qualifying and monitoring critical suppliers
  • Implement appropriate supplier agreements covering IVDR requirements
  • Establish clear roles and responsibilities for economic operators
  • Create systems for verifying unique device identification (UDI) implementation across the supply chain

5. Person Responsible for Regulatory Compliance (PRRC)
Designate a qualified person responsible for regulatory compliance who will:

  • Ensure product conformity is appropriately verified
  • Maintain technical documentation and EU declarations of conformity
  • Fulfill post-market surveillance obligations
  • Ensure reporting requirements for serious incidents are met

6. Documentation Strategy for IVDR
Documentation requirements under IVDR are extensive. Implement a systematic approach:

  • Update your quality manual to reflect IVDR-specific requirements
  • Revise existing internal procedues to incorporate new requirements and references
  • Develop new procedures for gaps identified in your analysis
  • Create templates for technical documentation aligned with Annexes II and III
  •  Implement document management systems capable of maintaining the necessary documentation throughout the product lifecycle


Conclusion: A Transformed Approach to Quality
IVDR compliance isn’t simply about updating documents, it represents a fundamental shift in how IVD manufacturers approach quality management. By systematically addressing each aspect of the regulation, you can transform your QMS from a documentation-focused system to a truly integrated approach that enhances product safety and performance.

It is recommended that you liaise with your certification/notified body, they may have further guidance on what they would like to see, and how to lay out specific documents and QMS infrastructure before any auditing takes place. Remember it is in everyone’s best interest to ensure manufacturers are compliant, including notified bodies and competent authorities. If you don’t have a notified body, this is a great place to start!


The investment in your QMS now will not only ensure regulatory compliance but also strengthen your market position through improved product quality and enhanced patient safety. Begin your IVDR transformation today to ensure continued access to the European market and position your organization for future growth in an increasingly regulated industry.

You can speak to us by booking in our calendar here, or email [email protected] to discuss investing into your QMS, whether that be QMS hosting or uplifting, IVDeology can support.